Clinical Effect of Encephabol (Pyritinol) in the Treatment of Cerebrovascular Disorders

Tazaki, Yuichi; Omae, Teruo; Kuromaru, Shoshiro; Ohtomo, Eiichi; Hasegawa, Kanae; Mori, Atsuyoshi; Kurihara, Masanao; Kutsusawa, Naoyuki; Okada, Tsugio

doi:10.1177/030006058000800203

Cited by 10 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…But it is in the 80s that various other classes of drugs considered active on the cerebrovascular disorders were introduced and proposed for clinical use. The first group was composed by the antioxidants pyritinol (Tazaki et al, 1980) and idebenone (Nakano et al, 1989) and was followed by a group including different vitamins, acetilcarnitine (Testa et al, International Psychogeriatrics, 15(Suppl. 1), 2003 1982) and folic acid (folates) (Fioravanti et al, 1997) and a group of compounds active on the phospholipid synthesis, cdp-choline (Agnoli et al, 1985) and alpha-glycerylphosphorylcholine (Di Perri, 1991).…”

mentioning

confidence: 99%

History of Symptomatic Therapy in Vascular Dementia

Fioravanti

2003

Int. Psychogeriatr.

View full text Add to dashboard Cite

The therapy for vascular dementia has known several changes and updates since the use of niacin in the first years of the 20th century. These modifications were due to the parallel evolution of the concept of vascular dementia. Initially, treatments in this area were proposed because they were considered vasoactive and able to increase the blood flow of the brain. After these, other drugs were introduced because they were also able to ameliorate the oxygen usage by the suffering neurons. The more recent therapeutic proposals were made for drugs active on the metabolic activities of the brain, or with hemorrheological or antioxidant properties. As a consequence, a large array of different pharmacological properties were considered in proposing the several different kinds of drugs as useful in vascular dementia patients. The most recent attempt in this field consists of evaluating the usefulness of traditional antidementia drugs (those with anticholinesterase action) in patients with a prevalence of cerebrovascular disorders.

show abstract

mentioning

confidence: 99%